AG
KLRS

Artal Group’s Kalaris Therapeutics KLRS Stock Holding History

Artal Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-286,833
Closed -$4.77M – 106
2024
Q2 		$4.77M Hold
286,833
– – 0.12% 58
2024
Q1 		$4.98M Hold
286,833
– – 0.13% 63
2023
Q4 		$4.49M Hold
286,833
– – 0.15% 56
2023
Q3 		$14.2M Hold
286,833
– – 0.61% 24
2023
Q2 		$22.4M Buy
286,833
+44,347
+18% +$4.22M 0.7% 22
2023
Q1 		$22M Hold
242,486
– – 1.31% 20
2022
Q4 		$28.6M Hold
242,486
– – 1.6% 18
2022
Q3 		$44M Buy
242,486
+141,470
+140% +$22M 1.88% 17
2022
Q2 		$9.06M Hold
101,016
– – 0.48% 41
2022
Q1 		$15.7M Hold
101,016
– – 0.66% 35
2021
Q4 		$30.1M Hold
101,016
– – 0.82% 31
2021
Q3 		$58.2M Hold
101,016
– – 1.3% 22
2021
Q2 		$45.9M Hold
101,016
– – 0.93% 24
2021
Q1 		$54.4M Hold
101,016
– – 0.96% 25
2020
Q4 		$89.3M Hold
101,016
– – 1.92% 12
2020
Q3 		$63.9M Buy
+101,016
New +$69M 1.55% 15

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Artal Group's KLRS Position: Q3 2024 in Review

Artal Group sold out of Kalaris Therapeutics (KLRS) in Q3 2024, closing a stake of 286,833 shares — an estimated $4.77M sold.

Artal Group first reported a position in KLRS in Q3 2020 and held it in 16 quarters. The position peaked at $89.3M in Q4 2020. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

  • Artal Group reported no remaining Kalaris Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 286,833 Kalaris Therapeutics shares in Q3 2024, an estimated $4.77M.
  • Artal Group first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 16 quarters.
  • Artal Group's Kalaris Therapeutics position peaked at $89.3M in Q4 2020.
  • 59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.